TEL AVIV: A single injection of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE is 85% effective in preventing symptomatic illness between 15 and 28 days after administration, an Israeli study found, a development that it could help guide policy makers in vaccine priorities around the world.
Some governments are debating whether to delay the second injection of the recommended two-dose regimen to make the most of the vaccine shortage.
The Israeli study, conducted by the government-owned Sheba Medical Center and published on Friday, also found a 75% reduction in all Covid-19 infections, symptomatic or asymptomatic, after the first injection. The peer-reviewed study was published in the British medical journal Lancet as a correspondence, which means that it represents the opinions of the authors and not the journal.
The data used was collected on the 9,109 health employees of the center, who began their vaccination process as of December 19.
“This is the first study to evaluate the effectiveness of a single dose of vaccine under real-life conditions and shows early effectiveness, even before the second dose was administered,” said Professor Eyal Leshem, director of the Center for Medicine. of Travel and Tropical Diseases of Sheba and one of the authors of the study.